Notably, tumor regression resulted from adoptive cell therapy (ACT) using endogenous tumor-infiltrating CD4+ T lymphocytes recognizing a mutant ERBB2 protein in a patient with metastatic epithelial carcinoma. This evidence concerns the gene ERBB2 and neoplasm.